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Abstract
Introduction: Muckle-Wells syndrome (MWS) is an inherited autoinflammatory disease characterized by fever, rash,
arthralgia, conjunctivitis, sensorineural deafness and potentially life-threatening amyloidosis. The NLRP3/CIAS1 E311K
mutation caused a heterogeneous phenotype of MWS in a large family. This study analyzes the clinical spectrum,
patterns of inflammatory parameters and reports on response to treatment.
Methods: A total of 42 patients and family members were screened for the presence of the NLRP3 mutation.
Clinical symptoms were reviewed in all family members. Classical (erythrocyte sedimentation rate (ESR, C-reactive
protein (CRP)) and novel MWS inflammatory markers (serum amyloid A (SAA), cytokines, cytokine receptor levels)
were determined. Patients were treated with the IL-1 inhibitors Anakinra or Canakinumab.
Results: All 13 clinically affected patients were heterozygous carriers of the amino acid substitution p.Glu311Lys/
E311K encoded by exon 3 of the NLRP3 gene, but none of the healthy family members. Disease manifestations
varied widely. Except for one child, all carriers suffered from hearing loss and severe fatigue. TNF-a, IL-6, TNF-RI,
and TNF-RII levels as well as SAA were elevated in three, two, one, six and ten patients, respectively. Both clinical
and laboratory parameters responded quickly and sustainedly to treatment with Anakinra or Canakinumab.
Conclusions: The NLRP3 E311K mutation is associated with a heterogeneous clinical spectrum, which may expand
the view on MWS presentation. The leading symptom was hearing loss. Pericarditis, a rare but severe clinical
feature of MWS, was diagnosed in three patients. One patient had a severe course, which led to renal failure
secondary to amyloidosis. IL-1 inhibition leads to rapid and sustained improvement of symptoms.
Introduction
Mutations in the NLRP3 gene (formerly known as
CIAS1) have been shown to cause a spectrum of autoin-
flammatory diseases including familial cold autoinflam-
matory syndrome (FCAS), Muckle-Wells syndrome
(MWS), and neonatal-onset multisystem inflammatory
disease (NOMID)/chronic infantile neurologic, cuta-
neous, and articular syndrome (CINCA) [1]. The least
severe disease in this spectrum is FCAS, which is
characterized by mild features including urticaria,
arthralgia, and fever after generalized exposure to cold.
Neonates and young children with the most severe clini-
cal phenotype NOMID/CINCA, in contrast, show
inflammatory central nervous system involvement
among many severe organ manifestations. MWS
patients can present with clinical features similar to
FCAS plus severe fatigue and arthritis. These patients
are commonly diagnosed once they develop progressive
sensorineural hearing loss. MWS patients are at high
risk for systemic amyloidosis, leading to renal failure in
up to 10% to 50% of patients [2,3]. The nomenclature of
these autoinflammatory diseases has been revised,
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(cryopyrin-associated periodic syndromes) [4].
Since the first report of genetic linkage between the
CIAS1 gene and MWS in 1999 by Cuisset [1], a total of
127 sequence variants for NLRP3/CIAS1 have been
identified and are registered in the INFEVERS database
(http://fmf.igh.cnrs.fr/infevers/) accessible via the World
Wide Web [5].
NLRP3 mutations are missense mutations located
mostly in exon 3 and involving the so-called NACHT
domain [6]. It is well recognized, however, that some
patients with a classical phenotype of FCAS, MWS, or
NOMID/CINCA may not have mutations in NLRP3,
suggesting the involvement of additional genes [7,8]. To
complicate matters even more, patients carrying the
identical amino acid substitution may present with dis-
tinctly different clinical subtypes [6]. This strongly sug-
gests that additional genetic and/or environmental
modifying factors are required to define the clinical phe-
notype. This challenges the concept that these condi-
tions are single-gene disorders.
With the advent of IL-1 inhibitors, such as Anakinra,
Rilonacept and Canakinumab, successful treatment of
patients with CAPS has for the first time become feasi-
ble [9-11]. Rapid resolution of acute symptoms, inflam-
matory parameters, and also improvement of long-term
disease sequelae have been reported [12-14].
T h ea i m so ft h i ss t u d yw e r e :1 )t oc h a r a c t e r i z et h e
clinical phenotype in a large, 42-member family includ-
ing 13 individuals carrying a NLRP3 E311K mutation; 2)
to determine classical inflammatory markers and MWS
biomarkers including pro-inflammatory cytokines and
their receptors in all patients; and 3) to describe the
response to IL-1 inhibition in this family.
Materials and methods
Index case
A 12-year-old girl presented with a two-year history of
recurrent fever episodes, arthralgia, arthritis, rash, con-
junctivitis, and sensorineural hearing loss. Classical
inflammatory markers including CRP and ESR were
strongly elevated. The diagnosis of MWS was suspected
based on the clinical presentation (in particular the sen-
sorineural hearing loss) and the elevated inflammatory
markers. Genetic testing revealed a heterozygous c.931G
> A mutation in exon 3 of the NLRP3 gene on chromo-
some 1q44, which results in the replacement of glutamic
acid (GAG) at amino acid position 311 by lysine (AAG),
thereby confirming the diagnosis of MWS. Written
informed consent to publish the case presentation was
obtained from the index patient’s parents.
Study design
A single center cohort study of consecutive family mem-
bers of the index case was conducted between March
2004 and January 2008. All MWS patients were followed
according to a standardized assessment protocol in the
institutional interdisciplinary Autoinflammatory Diseases
Clinic led by experienced pediatric and adult rheumatol-
ogists (JKD, IK). Written informed consent was obtained
from all family members and the study was approved by
the Institutional Review Board (IRB) of the Faculty of
Medicine of the University of Tübingen (REB No 326/
2007B01).
Family studies
The extended family of the index patient consisted of 42
living members, covering three generations. All 42
family members were screened by standardized ques-
tioning for MWS-associated symptoms. Genetic testing
for the NLRP3 mutation was performed in 36 family
members independent of their clinical status. Only
symptomatic patients with confirmed genetic mutation
received audiology assessments and ophthalmology
exams and MRI studies.
Demographics and clinical data
Demographic data included sex, ethnicity, and age at
diagnosis of MWS. Detailed information was collected
from standardized assessments obtained for all patients
at each visit. A targeted review of the family history was
conducted and included consanguinity, fever, infections,
eye disease (categories: conjunctivitis, uveitis, and papil-
lary edema), hearing loss, renal failure, hypertension,
musculoskeletal symptoms (categories: arthralgia, arthri-
tis, and myalgia), and rash (characteristics: cold-induced,
urticarial, and maculo-papular).
The review of systems included global measures of
patient health: 1) the Patient Global Health Score, a 10-
cm visual analogue scale (VAS); 2) the Patient Mood
S c o r e( V A S ) ,a n d3 )t h eP a t i e n tP e r f o r m a n c eG l o b a l
Score (VAS). Clinical symptoms including fever (pattern
and duration), headache, conjunctivitis, uveitis and
papillary edema, hearing loss, oral ulcers, abdominal
pain, renal involvement (proteinuria, hematuria, renal
failure), musculoskeletal symptoms (arthralgia, arthritis,
myalgia) and skin rash (cold-induced, urticarial, maculo-
papular) were recorded. A complete physical examina-
tion assessed all organ systems. Associated conditions,
MWS-related comorbidities including amyloidosis, and
potential complications of MWS and its treatment were
sought. A Physician Global Assessment Score (VAS) was
recorded at each visit. Patient follow-up assessments
were documented.
Muckle-Wells Syndrome - Disease Activity Score (MWS-
DAS)
The MWS-DAS was applied as described previously
[15]. This semi-quantitative score attributes one point to
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two points to severe symptoms. The maximum score of
the MWS-DAS is 20. Disease complications and seque-
lae including delayed puberty and amyloidosis are
recorded separately. Based on consensus judgment of all
participating experts, a MWS-DAS cutoff for mild dis-
ease (< 10 points) versus severe disease (≥ 10 points)
was chosen.
Laboratory data
Standardized laboratory testing was conducted at each
visit and included the classical inflammatory markers and
hematology tests, ESR, CRP, white blood cell count
(WBC), hemoglobin (HGB), platelet count (PTL), ferritin,
and fibrinogen. Serum concentrations of biomarkers and
cytokines, serum amyloid A (SAA), Interleukin 1 (IL-1),
Interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-a),
TNF receptor I (TNF-RI), and TNF receptor II (TNF-RII)
were analyzed by an enzyme-linked immunosorbent assay.
Renal function parameters included serum creatinine,
urea, uric acid, dipstick for blood and albumin, spot urine
for alpha 1-microglobulin and alpha 2-microglobulin, and
24-hour urine for creatinine clearance and proteinuria.
Other testing in patients with confirmed MWS
Audiology Assessment: Ear, Nose, and Throat (ENT)
examination and audiogram was performed at the time
of diagnosis to evaluate the status of hearing and every
six months thereafter as a follow-up. The audiology
examination included air-conduction thresholds for pure
tone frequencies at 250 to 8000 Hz, bone conduction
threshold, and tympanometry.
Ophthalmologic exam: A standardized ophthalmologic
evaluation was performed at diagnosis and then every
three months by an ophthalmology consultant, focusing
on visual changes that are sensitive in documenting
optic nerve function, conjunctivitis, and uveitis.
Magnetic resonance imaging (MRI): A gadolinium-
enhanced MRI was performed at diagnosis and then
every 12 months as a follow-up to assess meningitis and
cellular infiltrates and the inner ear.
Treatment
Patients received Anakinra, the chimeric monoclonal IL-
1 receptor antagonist, at a dose of 1 to 2 mg/kg/day in
patients < 40 kg body weight and at 100 mg/dose ≥ 40
kg body (Kineret; Amgen, Cambrige, UK). The drug was
self-administered by subcutaneous injection once daily.
In children with persistent disease activity the Anakinra
dose was stepwise escalated to a maximum of 8 mg/kg.
Concurrent non-steroidal anti-inflammatory medication
was added if required.
Patients were treated with Canakinumab, the fully
humanized anti-IL-1 monoclonal antibody, at a dose of
150 mg s.c. for ≥ 40 kg body weight or 2 mg/kg for <
40 kg body weight. In patients who did not achieve
complete remission by day 8, Canakinumab was admi-
nistered at a dose of 5 mg/kg body weight intravenously.
Patients were allowed to switch anti-IL-1 therapy for
lack of efficacy or for patient preference. Upon disconti-
nuation of Anakinra a disease flare had to be awaited.
The maximum wait time prior to start of Canakinumab
therapy was set at 14 days.
Statistical analysis
All clinical, laboratory, and MWS-DAS data were
entered into a designated ARDIS research database.
Baseline demographic data were analyzed using descrip-
tive statistics. Characteristics of the mild MWS cohort
(MWS-DAS < 10) and the severe MWS cohort (MWS-
DAS ≥ 10) were compared using Student’s t-test for
continuous data and the chi-square analysis of Fisher’s
exact test for categorical variables. All analyses were
performed using SAS statistical software (version 8; SAS
Institute, Cary, NC).
Results
Patients
The study included all 42 living members of the index
patient’s family, 17 males and 25 females. The pedigree
is depicted in Figure 1. All members completed the
questionnaire for MWS-related symptoms, 36 under-
went genetic testing. None of the previously described
NLRP3/CIAS1 mutations was found. Instead, a mutation
was identified in 13 of the 42 family members, causing a
substitution of glutamic acid by lysine at amino acid
position 311 (p.Glu311Lys or E311K). All 13 clinically
affected family members were heterozygous carriers of
this substitution which is encoded by exon 3 of the
NLRP3 gene (see Table 1).
Clinical presentation
All positively tested family members had evidence of
MWS-associated symptoms. The most common one
was hearing loss, seen in 12 patients (92%). Arthralgias
were reported in 11 (85%), arthritis, which had
improved with age, in nine patients (69%), and myalgia
in 7 patients (54%). Seven patients (54%) described an
erythematous, non-urticarial rash, appearing indepen-
dent of cold exposure. Febrile episodes were reported
only by four patients (31%), lasting on average between
three and five days. The maximum temperature per epi-
sode ranged between 39°C and 40°C. All patients had
constitutional symptoms, in particular chronic, severe
fatigue. Seven patients (54%) reported recurrent episodes
of headaches but without any corresponding abnormal-
ity in MRI examination. Ocular symptoms such as con-
junctivitis, uveitis, or opticus neuritis were found in 11
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of pericarditis (23%) long before the diagnosis of MWS
was made. Presentation of pericarditis at that time was
typical with thoracic pain and shortness of breath and
treatment had consisted of NSAID and corticosteroids.
Pericarditis had not re-occurred since, with or without
IL-1 inhibition.
MWS-DAS was calculated at the baseline time point
before the start of IL-1 inhibition for all patients. Five
(38%) patients met the criteria for mild MWS activity,
while severe disease was present in eight (62%). The
mean MWS-DAS was 9.6 with a range between 4 and 14.
Patient-derived measures at baseline had the following
means and standard deviations: 1) Patient Global Health
Score: 4.77 (2.20); 2) Patient Mood Score: 2.08 (0.49); and
3) Patient Performance Global: 5.85 (2.15). The Physician
Global Assessment Score had a mean of 5.85 (1.52). The
spectrum of clinical features is summarized in Table 2.
Correlation between genotype and phenotype
All 13 family members with MWS-associated clinical
symptoms were found to be heterozygous carriers of the
novel E311K mutation, while none of the healthy family
members carried this genetic mutation. The genotype/
phenotype correlation was therefore 100%. All mutation
carriers reported that they had been symptomatic since
childhood.
 
Figure 1 42 family members were interviewed and examined for signs and symptoms of MWS. Symptomatic family members are
depicted in grey, asymptomatic members in white. All 13 clinically symptomatic patients are carriers of the NLRP3 E311K mutation (grey).
Asymptomatic family members, who were not genetically tested, are marked in stripes. Clinical status of the deceased great-grandparents
generation (X) was reported by children (one affected, one asymptomatic).
Table 1 Demographic characteristics and NLRP3 gene
mutation status in an extended family with Muckle-Wells
syndrome
Extended family
Family members screened Number = 42
(100%)
Male:female 17:25
Gender ratio 1:1.5
Family members with MWS-associated symptoms
Symptomatic family members 13/42 (31%)
Family members with confirmed NLRP3 mutation
Heterozygous carriers 13/42 (31%)
Male:female 5:8
Gender ratio 1:1.6
Age at MWS diagnosis (mean and range) 37.8 years
(3.3 - 72.4)
Symptomatic family members with the E311K mutation 13/13 (100%)
MWS, Muckle-Wells syndrome
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Elevated classical inflammatory markers were found in
the vast majority of patients. An increased ESR was seen
in 7 patients (54%) and an elevated CRP in 13 (100%).
Fibrinogen abnormalities were found in five (38%) and
raised ferritin in three patients (23%). Five patients
showed neutrophilia (38%).
Serum SAA levels, which may be regarded as a MWS
biomarker were elevated in ten patients (77%). Increased
IL-6 concentrations were observed in five patients
(38%), while seven patients (54%) had high TNF-a
serum levels. TNF-RI and TNF-RII were elevated in two
patients. None of the patients had elevated serum IL-1
levels. Impaired renal function was rarely seen. Raised
serum creatinine, urea, and uric acid were present only
in the patient with renal failure. However, urine analyses
demonstrated increased urine a1-microglobulin in five
and increased a2-microglobulin in two patients. All
laboratory test results are summarized in Table 3.
Association with severe disease
Parameters significantly associated with severe MWS
disease (MWS-DAS ≥ 10) were female gender (P =
0.01), musculoskeletal involvement (P < 0.05), eye invol-
vement (P < 0.05) and the global measures Patients Glo-
bal Health Score (P = 0.014) and Physicians Global
Assessment Score (P = 0.0015). None of the laboratory
parameters correlated significantly with disease severity.
Treatment
Anakinra was given to 7/13 (54%) family members, 10/
13 (77%) received Canakinumab. Six patients switched
to Canakinumab after being treated with Anakinra. Rea-
sons for switching from Anakinra to Canakinumab were
inconvenience of daily injections and secondary treat-
ment failure in two children. The response of clinical
and laboratory parameters was rapid and profound for
both substances. MWS-DAS decreased from 9.6 to 6
with Anakinra, and from 5.9 to 2.7 with Canakinumab.
ESR (mm/h) decreased from 30 to 14 with Anakinra,
SAA (mg/l) decreased from 35.9 to 6.8 with Anakinra
and from 27.6 to 4.7 with Canakinumab and CRP (mg/
dl0 decreased from 2.26 to 0.64 with Anakinra and from
2.25 to 0.23 with Canakinumab. Hearing improved in
three patients, one treated with Canakinumab and two
with Anakinra.
Discussion
This study identified a mutation in the NLRP3 gene
causing the autosomal dominantly inherited autoinflam-
matory Muckle-Wells syndrome. We were able to char-
acterize the clinical phenotype, the associated laboratory
parameters and the genotype in an extended family after
confirming MWS in the index patient. A total of 13
family members were found to be heterozygous carriers
of the E311K mutation encoded by exon 3 of the
NLRP3 gene on chromosome 1. All 13 mutation-positive
individuals were symptomatic. In contrast, none of the
mutation-negative family members showed signs or
symptoms associated with MWS.
This family study illustrates the heterogeneous clinical
spectrum and the variability of disease severity asso-
ciated with the E311K mutation. Classical inflammatory
markers and MWS biomarkers were determined in all
E311K-positive MWS patients. CRP was found to be
strongly associated with active disease. The study also
Table 2 Clinical features of all patients with the NLRP3
E311K mutation
NLRP3 mutation,
N=1 3
Clinical symptoms
Constitutional symptoms
Fatigue 13 (100%)
Recurrent fever 4 (31%)
Organ-specific symptoms
Headache 7 (54%)
Ocular symptoms: 11 (85%)
■ Conjunctivitis 10 (77%)
■ Uveitis 2 (15%)
■ Papillary edema 0
■ Opticus neuritis 1 (8%)
Sensorineural hearing loss 12 (92%)
Oral ulcers 6 (46%)
Pericarditis 3 (23%)
Abdominal pain 4 (31%)
Renal disease/proteinuria 10 (77%)
Musculoskeletal symptoms: 11 (85%)
■ Arthralgias 11 (85%)
■ Arthritis 9 (69%)
■ Myalgias 7 (54%)
Skin symptoms: 7 (54%)
■ Erythematous rash 7 (54%)
■ Cold-induced urticaria 0
MWS Disease Activity Score (MWS-DAS)
Mean MWS-DAS (range) 9.6 (4-14)
mild (< 10) 5 (38%)
severe (≥ 10) 8 (62%)
Global measures of health (patient-derived)
Patient Global Health Score VAS (mean and stdv) 4.77 (2.20)
Patient Mood Score VAS (mean and stdv) 2.08 (0.49)
Patient Performance global score
Global VAS (10 = severe)
(mean and stdv)
5.85 (2.15)
Physician Global Assessment Score VAS
(mean and stdv)
5.85 (1.52)
MWS, Muckle-Wells syndrome; MWS-DAS, MWS Disease Activity Score; NLRP3,
NLR family, pyrin domain containing 3; stdv, standard deviation; VAS, visual
analogue scale;
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Number of individuals (%)
with elevations and associated levels
Classical inflammatory markers (normal)
Elevated ESR (< 22 mm/h)
Number (%) 7/13 (54%)
Mean mm/h (stdv) 31 (20-55 mm/h)
Elevated CRP (< 0.5 mg/dl)
Number (%) 13/13 (100%)
Mean (stdv) 2.25 (0.66-5.6)
Elevated Ferritin (< 30 μg/dl)
Number (%) 3/13 (23%)
range 33-48 μg/dl
Elevated Fibrinogen (< 170 mg/dl)
Number (%) 5/13 (38%)
range 439-540 mg/l
Hematological abnormalities
Patients with hemoglobin abnormalities (%) 0/13 (0%)
Patients with leukocytosis (%) 6/13 (46%)
Mean leucocyte count/μl (range) 10,507 (7,170-21,200)
Patients with neutrophilia (%) 5/13 (38%)
Mean neutrophil count/μl (range) 7,695 (3434-18211)
Patients with thrombocytosis (%) 0/13 (0%)
Biomarkers and cytokines
Serum amyloid A (SAA) (< 10 mg/l)
Number (%) 10/13 (77%)
mean (range) 40.7 (10-254)
Interleukin-1 (IL-1) (< 5 pg/ml)
Number(%) 0/8 (0%)
mean (range) 0.52 (0.2-1.48)
Interleukin-6 (IL-6) (< 5 pg/ml)
Number (%) 5 (38%)
mean (range) 6.37 (5.9-15.7)
Tumor necrosis factor a (TNF-a) (< 8 pg/ml)
Number (%) 7 (54%)
mean (range) 9.37 (8,2-16.5)
TNF receptor I (TNF-RI) (< 1,966 pg/ml)
Number (%) 2 (15%)
mean (range) 1,970-> 5,000
TNF receptor II (TNF-RII) (< 3,170 pg/ml)
Number (%) 2 (15%)
mean (range) 3,210-> 5,000
Proteinuria
Elevated total urine protein 10/13 (77%)
Elevated alpha 1-microglobulin [μg/ml] 5/13 (28%)
range 13.2-262
Elevated alpha 2-microglobulin (mg/l) 2/13 (15%)
range 0.3-> 1.2
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; IL-1, Interleukin-1; SAA, Serum amyloid A; TNF-a, Tumor necrosis factor a; TNF-RI, TNF receptor I;
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MWS, although there was no linear correlation between
levels of laboratory parameters and disease severity. The
single amino acid substitution of glutamic acid by lysine
at residue 311 leads to the synthesis of a modified cryo-
pyrin, which in these patients may have induced the
increased release of proinflammatory cytokines such as
IL-6 (38%), and TNF-a (54%) as well as SAA (77%). The
classical inflammatory markers CRP (100%) and ESR
(54%) were also elevated.
The classical inflammatory markers including CRP
were increased in all MWS patients carrying the E311K
mutation, while ESR was elevated in 54%. However, the
increase was only modest and depended on the actual
disease activity. In comparison to E311K carriers, the
median values of other cohorts [10] were higher. When
elevated, the biomarkers SAA, IL-6 and TNF-a in con-
trast, correlated closely with the autoinflammatory state.
SAA appeared to have the highest sensitivity for inflam-
mation in this MWS family. Patients with raised SAA
levels are at an increased risk of renal impairment due
to progressive deposition of amyloid in the kidneys [2].
Accordingly, there is a strong correlation between SAA
levels and proteinuria.
In agreement with the clinical phenotype and the
moderate elevation of classical inflammatory markers,
cytokine levels were only modestly raised in our cohort.
Not surprisingly, serum IL-1 levels were not elevated in
this cohort, reflecting the short serum IL-1 half-life as
shown in previous studies [16]. Hoffman et al.d e m o n -
strated that serum IL-1 levels in FCAS patients with
NLRP3 mutations were normal; however, extensive
amounts of IL-1 protein and IL-1 mRNA were found in
the affected skin [16].
All heterozygous carriers of the E311K mutation
showed the clinical picture of MWS and had in the past
sought medical attention or were even hospitalized
mainly for joint problems (85%) without further speci-
fied diagnosis. All E311K mutation-positive MWS
patients suffered from severe fatigue, which had signifi-
cant impact on their quality of life. Of note, patients
predominantly complained of arthralgias/arthritis at a
younger age. In contrast, MWS-associated progressive
hearing loss (92%) occurred only later in the disease
course. Until the teenage years, all patients had a history
of normal hearing; however, mild changes in the audio-
gram in the high upper frequencies were noticed as
e a r l ya ss i xy e a r so fa g e .A sa d u l t s ,a l la f f e c t e di n d i v i -
duals required hearing aids. Surprisingly, fever as the
leading symptom of autoinflammatory syndromes in
children occurred in only 31% of our patients and then
predominantly during childhood. The febrile episodes
reported lasted on average between three and five days.
The maximum temperature per episode ranged between
39°C and 40°C, showing the typical MWS fever pattern.
There was only one MWS case with end-stage renal fail-
ure. However, mild renal impairment, as measured by
urine a1-microglobulin and a2-microglobulin, was
found in 77% of the patients. Three patients experienced
one episode of pericarditis, which has so far only been
reported in MWS-patients with the E311K mutation
[17]. Following the first report [18] the NLRP3 E311K
mutation has been described so far in 7 more patients
[13,17,19] in addition to the 13 affected patients pre-
sented here. In accordance with the four patients
reported by Murphy et al. [17], hearing loss and joint
involvement was also predominant in our cohort and
rash occurred only in 54% of patients. Although transi-
ent urticarial rash was described in the patient reported
by Mirault [13], clinical presentation was also consid-
ered ‘uncommon’ by the authors with regard to the typi-
cal presentation of MWS. Pericarditis was also reported
in one of four patients by Murphy et al [17], which may
indicate that pericarditis has to be considered as one
feature in MWS, at least in patients with this particular
mutation (observed in 4/20 (20%) E311K patients).
Our patients responded promptly to IL-1 inhibition in
contrast to the treatment response described by Murphy
et al. Improvement of hearing loss following IL-1 inhibi-
tion was reported by three of four patients in the case
series of Murphy et al. [17] and also in the patient
described by Mirault [13]. In our cohort, 3 of the 11
treated patients showed improved hearing. The first
report by Muckle and Wells described the clinical fea-
tures of rash, fever, severe fatigue, arthralgia, deafness,
and amyloidosis as sequelae [20]. All of these core
symptoms were also found in our patients, as well as
additional features such as conjunctivitis, uveitis, and
headaches. Cold-induced flares, papillary edema, or
frontal bossing as reported by Hawkins et al. [21], how-
ever, were not present in our family. In our view, the
clinical presentation of patients with the NLRP3 E311K
mutation may indeed expand the recognized spectrum
of MWS features, which makes it even more difficult to
give a definition of ‘usual’.
There was a 100% correlation between genotype and
phenotype in our MWS patients, although the pheno-
type was quite heterogeneous. Analysis of the genotype
and phenotype performed by Aksentijevich et al., in
contrast, demonstrated that only 2 of the 29 probands
studied had the distinct clinical picture of MWS. Most
of the others presented either with FCAS, FCAS/MWS,
MWS/NOMID, or NOMID [22]. The clinical heteroge-
neity of patients carrying the same mutation is poorly
understood [23]. The observation, that the identical
amino acid substitution is associated with different clini-
cal subtypes [6] suggests that NLRP3 mutations do not
solely account for the phenotype. Reports from several
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or environmental factors can influence phenotype and
disease severity [6,23,24].
Because favorable response to IL-1 inhibition in
patients with the E311K mutation has been reported
e x t e n s i v e l yb e f o r e[ 1 1 , 1 2 ] ,o n l yab r i e fd e s c r i p t i o no n
response to treatment in this particular cohort is given
in this study. In addition to the effects on clinical and
laboratory parameters it is remarkable, that long-term
sequelae such as hearing loss are improved by therapy
in some of these patients.
Conclusion
This is the largest cohort of MWS patients carrying the
NLRP3 E311K mutation described to date. The hetero-
geneous clinical presentation of patients with this parti-
cular mutation may expand the features expected in
MWS so far. Early accurate diagnosis, if possible assisted
by genetic confirmation of mutation is important, since
IL-1-blocking agents have been very efficacious in
patients with MWS [16,21,25] and early therapeutic
intervention is necessary to prevent irreversible organ
damage and, in particular, hearing loss [12,13,17].
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